XML 19 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (51,663) $ (54,831)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation, amortization and accretion 1,787 2,058
Stock-based compensation expense 2,516 2,628
Loss on extinguishment of debt 830  
Gain on disposal of property and equipment (24)  
Loss on foreign currency translation 8,392 2,023
Interest incurred through borrowings under Sanofi Loan Facility   2,604
Interest on note payable to principal stockholder 1,435 1,443
Warrant issuance cost   653
Change in fair value of warrant liability (6,776) 5,306
Other, net 114 717
Changes in operating assets and liabilities:    
Accounts receivable, net (1,010) 23
Receivable from Sanofi 30,557  
Inventory (841) (2,866)
Deferred costs from commercial product sales (191)  
Prepaid expenses and other current assets 1,800 2,595
Other assets 125 (238)
Accounts payable 3,357 (12,532)
Accrued expenses and other current liabilities (483) 2,663
Deferred payments from collaboration (125) 9,379
Deferred revenue-net (827)  
Recognized loss on purchase commitments (500) (3,892)
Net cash used in operating activities (11,527) (42,267)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment   (1,144)
Net proceeds from sale of asset held for sale 16,651  
Proceeds from sale of property and equipment 24 17
Net cash provided by (used in) investing activities 16,675 (1,127)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock   734
Proceeds from direct placement   50,000
Issuance cost associated with direct placement   (2,678)
Borrowings on note payable to principal stockholder 19,429  
Principal payments on facility financing obligation (4,000)  
Payment of employment taxes related to vested restricted stock units (88) (3)
Net cash provided by financing activities 15,341 48,053
NET INCREASE IN CASH AND CASH EQUIVALENTS 20,489 4,659
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 22,895 59,074
CASH AND CASH EQUIVALENTS, END OF PERIOD 43,384 63,733
SUPPLEMENTAL CASH FLOWS DISCLOSURES:    
Interest paid in cash, net of amounts capitalized 4,141 4,608
NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Repayment of facility financing obligation through issuance of common stock 11,000  
Capitalization of interest on note payable to principal stockholder $ 10,716  
Reclassification of deferred payments from collaboration to Sanofi Loan Facility and loss share obligation   5,003
Reclassification of deferred costs from loss on purchase commitment to deferred costs from collaboration   $ 9,202